Lead Sponsor

Novartis Pharmaceuticals

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

•Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and:
•* Smoking history of at least 10 pack-years
•* Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≤ 65% and ≥ 30% of the predicted normal value
•* Post-bronchodilator FEV1/FVC (forced vital capacity) \< 70%

•Patients who have received systemic corticosteroids and/or antibiotics and/or was hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period
•Patients who have had a respiratory tract infection within 6 weeks prior to screening
•Patients with concomitant pulmonary disease
•Patients with a history of asthma
•Patients with diabetes Type I or uncontrolled diabetes Type II
•Any patient with lung cancer or a history of lung cancer
•Patients with a history of certain cardiovascular comorbid conditions

Related studies

NCT07307781 · Chronic Obstructive Pulmonary Disease (COPD)

NCT07509606 · Chronic Obstructive Pulmonary Disease (COPD), Whole Body Vibration

NCT07451977 · Chronic Respiratory Failure, Hypoxemia, and more

NCT07477600 · Chronic Obstructive Pulmonary Disease (COPD)

NCT07082738 · Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease